Clinical Trial

Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

Study acronym: ACCOMPLISH
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
* Clinical Indication : Advanced adrenal cortical carcinoma after platinum-based chemotherapy * Trial Type : Single arm, prospective trial * Route of administration : Intravenous (pembrolizumab) and peroral (lenvatinib) * Treatment Groups : Single arm * Number of trial participants : 30
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-08-30; most recent amendment 2026-01-22.
Status change: Enrolling by Invitation → Active, Not Recruiting 2026-01-22
Status change: Not Yet Recruiting → Enrolling by Invitation 2023-11-23
Trial Details
NCT Number NCT05036434
Lead Sponsor National Cancer Center, Korea
Collaborators: MSD Korea Ltd.
Conditions Adrenocortical Carcinoma
Enrollment 30 participants
Start Date 2021-11-15
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-01-23